<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295304</url>
  </required_header>
  <id_info>
    <org_study_id>NR-DOC-14670</org_study_id>
    <nct_id>NCT04295304</nct_id>
  </id_info>
  <brief_title>NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases</brief_title>
  <acronym>NR</acronym>
  <official_title>Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nano Retina</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nano Retina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to demonstrate safety of the NR 600 System, and to evaluate the
      performance of the device in restoring visual activity of daily living in subjects with
      retinal degenerative diseases and severe visual impairment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NR600 is a retinal prosthetic system intended to provide electrical stimulation to the
      retina to induce visual perception in patients with severe to profound vision loss due to
      degenerative retinal disease. The system is consisting of an autonomous epiretinal implant
      with penetrating electrodes, Glasses and a Clinician Station. The implant is Infrared (IR)
      powered and is designed to convert visual input into well-defined electrical stimulation
      patterns suited to elicit neuronal retina activity. All study subjects will be implanted with
      the device in one eye and will be followed for 18-months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>within 9 months post implantation</time_frame>
    <description>Occurrence of serious adverse events related to the device and/or to the procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Retinal Degeneration</condition>
  <arm_group>
    <arm_group_label>NR600 device implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retinal surgery and implantation of epi-retinal prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Retinal surgery with implantation of epi-retinal device</intervention_name>
    <description>Retinal surgery and implantation of epi-retinal prosthesis</description>
    <arm_group_label>NR600 device implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have confirmed diagnosis of end-stage hereditary outer retinal degeneration such as RP
             or cone-rod dystrophy

          -  Visual acuity in both eyes from light perception to no light perception

          -  Confirmed functional ganglion cells and optic nerve in the implanted eye

          -  History of useful vision

          -  Mentally competent

        Exclusion Criteria:

          -  Diseases or condition that affect retinal and or optic nerve function

          -  Optic Nerve diseases

          -  Diseases or conditions that, in the judgement of the surgeon, impede the ability to
             implant the device or would prevent the system from functioning

          -  Dry eye

          -  Pre-disposition to eye rubbing

          -  Posterior pole severe staphyloma

          -  Strabismus superior to 10 prismatic diopter

          -  Severe nystagmus

          -  Corneal endothelium density &lt; 1500 cells/mm2

          -  Refractive error ≥±8 diopters spheric and 3.5 diopter cylindric

          -  Currently pregnant (female subject) or inadequate contraceptive treatment in female
             subjects &lt;50 years of age.

          -  Hyperthyroidism or hypersensitivity to iodine

          -  Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression)

          -  Participation in another study with any investigational drug or device that may
             conflict with the objectives, follow-up or testing of this study

          -  Conditions likely to limit life to less than 1 year from time of recruitment to the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weinberger Dov, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Retinal surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rigler</last_name>
    <phone>+972747377640</phone>
    <email>dudur@nano-retina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Vriens</last_name>
      <phone>+ 32 16 33 23 73</phone>
      <email>fingeborg.vriens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Stalmans, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Calcagno, Dr.</last_name>
      <phone>+39 0226436212</phone>
      <email>calcagno.francesca@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Bandello, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico A. Gemelli, IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Falsini Benedetto, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Stanislao Rizzo, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

